Kevin Smith

Labcorp is pleased to introduce our new Pulse of the Lab Leader report. This report highlights the obstacles lab leaders face, the innovative solutions they are pioneering and the support they need from the healthcare community. From staffing shortages and regulations to budget constraints and limited access to new technology, lab leaders make difficult decisions daily that affect patient testing and diagnosis. Explore The Pulse of the Lab Leader to see what other lab leaders are saying, help benchmark your lab and assist in your strategic planning: https://lnkd.in/gw_2cnGF #LabLeaders

7

📢 Check out our report on the explosive growth of the Cell and Gene Therapy (CGT) industry in Greater Philadelphia! 🌟 #LeadingLifeSciences! The region is now the nation’s #2 CGT hub, serving as home to 60 of the estimated 500 CGT companies worldwide. Dive into the report here: https://lnkd.in/edNneij9

8

Drug-Linker manufacturing and ADC conjugation facilities require specific regulatory knowledge and an engrained safety culture. They also bring their own unique design, construction and operational challenges. My presentation at INTERPHEX Global has generated some really great conversations about the future of this modality and how we plan to push towards that future. Let's keep the discussion going - what are your biggest challenges when designing and operating these complex facilities? #CRB #ADC #AntibodyDrugConjugate

33

We're excited to share that our collaborative project on Fabry disease(LA-GLA, code name: HM14521/GC1134A) with Hanmi Pharmaceutical, has just earned Orphan Drug Designation(ODD) from the FDA! Living with Fabry disease means enduring the inconvenience of bi-weekly, hours-long IV treatments at the hospital. But here comes LA-GLA, a game-changer! It's the first-ever treatment to offer a once-a-month subcutaneous injection, breaking new ground beyond the limitations of existing therapies. LA-GLA is proving superior to current treatments, with significant improvements noted in kidney function, vascular health, and peripheral nerve disorders. This February, two pivotal studies showcasing its benefits were presented at the WORLD Symposium 2024 in San Diego. Buoyed by these promising results, we are gearing up to file an IND application this year. *Fabry disease is a genetic disorder linked to the X chromosome, caused by deficient levels of the enzyme alpha-galactosidase A. This deficiency leads to cellular toxicity and inflammation, progressively damaging various organs and potentially escalating to a severe, life-threatening condition. https://lnkd.in/evM9FCGT #Fabry #LAGLA #ODD #FDA #Innovation #Partnering #Collaboration

126

1 Comment

On November 6, 2013, 25 Medical Information leaders from 18 pharmaceutical companies came together at BMS in Plainsboro, NJ to engage in a roundtable dialogue about potential cross-industry collaboration. We recently revisited the discussion notes and outputs from that unprecedented meeting. The collective goal was to develop an organization that addressed alignment across the industry to deliver potential solutions for overall better patient care and deliver an action plan on moving forward on a collaborative, cross-company solution, called the Drug Information Database, open to all US Healthcare Professionals. Months later, phactMI was formed. Today, all of those goals are now phactMI’s reality. #medicalinformation #medinfo #pharma #medicalaffairs #druginformation

34

2 Comments

Sagesse Bio is an early stage pharmaceutical company utilizing RNAi technology to accelerate the clinical development of novel solutions to destroy or remodel undesirable pockets of fat. The company's lead compound, SGY-101, is IND-enabled and currently in Phase II clinical trials for other indications. Sagesse Bio will promptly begin clinical evaluation of SGY-101 with comprehensive scientific and technical support from Sirnaomics which specializes in the development of RNAi technology. Initial indications of interest include body contouring and fat reduction. The strategic goal of Sagesse Bio is to become the leading provider of therapeutic solutions for targeted fat reduction in both medical dermatology and aesthetic medicine. 

3

Researchers at the University at Buffalo are working to improve the diagnosis and treatment of complex, potentially devastating diseases like Alzheimer's through protein mapping, or proteomics. Jun Qu, PhD., the group leader of the Proteomics and Bioanalysis lab, has seen improvements in the speed of his research using the Orbitrap Astral Mass Spectrometer. According to Qu, "If we used traditional biochemical technology, it might take decades to test each protein in a project like this. Here, we take a very small sample, and we can quantify 10,000 proteins in seconds." Read more about how Qu and his team are helping advance the understanding of diseases and ultimately keep the world healthier using our newest equipment:

9

1 Comment